Literature DB >> 34052572

Anti-infectious decontamination strategies in Dutch intensive care units: A survey study on contemporary practice and heterogeneity.

J H Elderman1, D S Y Ong2, P H J van der Voort3, E-J Wils4.   

Abstract

PURPOSE: Despite increasing evidence and updated national guidelines, practice of anti-infectious strategies appears to vary in the Netherlands. This study aimed to determine the variation of current practices of anti-infectious strategies in Dutch ICUs.
MATERIALS AND METHODS: In 2018 and 2019 an online survey of all Dutch ICUs was conducted with detailed questions on their anti-infectious strategies.
RESULTS: 89% (63 of 71) of the Dutch ICUs responded to the online survey. The remaining ICUs were contacted by telephone. 47 (66%) of the Dutch ICUs used SDD, 14 (20%) used SOD and 10 (14%) used neither SDD nor SOD. Within these strategies considerable heterogeneity was observed in the start criteria of SDD/SOD, the regimen adjustments based on microbiological surveillance and the monitoring of the interventions.
CONCLUSIONS: The proportion of Dutch ICUs applying SDD or SOD increased over time. Considerable heterogeneity in the regimens was reported. The impact of the observed differences within SDD and SOD practices on clinical outcome remains to be explored.
Copyright © 2021 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Anti-infective agents; Decontamination; Gastrointestinal tract; Intensive care units; Prevention and control; Surveys and questionnaires

Year:  2021        PMID: 34052572     DOI: 10.1016/j.jcrc.2021.05.001

Source DB:  PubMed          Journal:  J Crit Care        ISSN: 0883-9441            Impact factor:   3.425


  1 in total

1.  Ventilator-associated pneumonia in critically-ill patients with COVID-19 in a setting of selective decontamination of the digestive tract.

Authors:  Sinta B van der Meer; Grace Figaroa; Peter H J van der Voort; Maarten W Nijsten; Janesh Pillay
Journal:  Crit Care       Date:  2021-12-20       Impact factor: 9.097

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.